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ABSTRACT
Objectives: To identify negative symptoms in the
clinical records of a large sample of patients with
schizophrenia using natural language processing and
assess their relationship with clinical outcomes.
Design: Observational study using an anonymised
electronic health record case register.
Setting: South London and Maudsley NHS Trust
(SLaM), a large provider of inpatient and community
mental healthcare in the UK.
Participants: 7678 patients with schizophrenia
receiving care during 2011.
Main outcome measures: Hospital admission,
readmission and duration of admission.
Results: 10 different negative symptoms were
ascertained with precision statistics above 0.80. 41%
of patients had 2 or more negative symptoms. Negative
symptoms were associated with younger age, male
gender and single marital status, and with increased
likelihood of hospital admission (OR 1.24, 95% CI
1.10 to 1.39), longer duration of admission
(β-coefficient 20.5 days, 7.6–33.5), and increased
likelihood of readmission following discharge
(OR 1.58, 1.28 to 1.95).
Conclusions: Negative symptoms were common and
associated with adverse clinical outcomes, consistent
with evidence that these symptoms account for much
of the disability associated with schizophrenia. Natural
language processing provides a means of conducting
research in large representative samples of patients,
using data recorded during routine clinical practice.
INTRODUCTION
Negative symptoms, which include amotiva-
tion, a ﬂattening of emotional responses, a
reduction in speech and activity, and social
withdrawal,1 contribute to much of the dis-
ability associated with schizophrenia.2 These
symptoms are also associated with poor
psychosocial functioning3 and a reduced like-
lihood of remission.4–9 The aetiology and
pathophysiology of negative symptoms are
unknown, and there are no effective
treatments.10 11
A number of excellent rating scales have
been developed to assess negative symp-
toms.12–14 However, these are relatively
detailed, require a trained rater, and are not
routinely applied in clinical practice. As a
result, much of our knowledge of negative
symptoms is derived from studies in relatively
small samples of patients, who may have
been selected for inclusion because they had
particularly severe symptoms. The ﬁndings
Strengths and limitations of this study
▪ This is the largest known study (over 7000 parti-
cipants) to investigate the relationship of nega-
tive symptoms with clinical outcomes in people
with schizophrenia. Our findings demonstrate
that negative symptoms are present in a substan-
tial number of people with schizophrenia and are
associated with increased hospital admission,
readmission and duration of inpatient stay.
▪ To our knowledge, this is the first published
study to use an automated information extraction
method to acquire data on negative symptoms
from electronic health records. This approach
permits rapid acquisition of negative symptom
data which is representative of everyday clinical
practice in secondary mental healthcare.
▪ Our findings are based on data recorded by clini-
cians delivering routine mental healthcare who
were not specifically ascertaining negative symp-
toms. It is therefore possible that negative symp-
toms were not comprehensively documented in
the electronic health records from which they
were identified leading to an inaccurate estimate
of their prevalence in the analysed sample.
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from these samples may not therefore be representative
of negative symptoms in the overall population of
patients with schizophrenia.
Clinical information is increasingly recorded electron-
ically, facilitating access of rich clinical data, including
presence or absence of symptoms,15 from routine
medical records. In the present study, we used a novel
information extraction tool to identify negative symp-
tomatology in a large body of electronic records
collected from individuals with schizophrenia.16–18 We
then examined the relationship between negative symp-
toms and clinical outcomes. We tested the hypothesis
that negative symptoms are common in patients with
schizophrenia, and are associated with poor clinical
outcome, as indexed by the frequency and duration of
hospital admissions.
METHODS
Participants and clinical data
The study was carried out using the South London and
Maudsley NHS Foundation Trust (SLaM) Biomedical
Research Centre (BRC) Case Register, comprising elec-
tronic health record data dating back to April 2006 from
a large mental healthcare provider to 1.2 million resi-
dents of southeast London (UK). The data were interro-
gated using the Clinical Record Interactive Search
(CRIS) application,19 with a robust anonymisation
process and patient-led oversight.20 Three samples were
identiﬁed for analysis:
I. Sample A (n=7678): patients with schizophrenia
(International Classiﬁcation of Diseases (ICD)-10
F20.XX) aged 16 years and over who had used
SLaM services during 2011. This sample was used to
investigate: (1) the relationship between negative
symptoms, documented at any point in the elec-
tronic health record, and demographic and other
clinical measures (described below); (2) the rela-
tionship between negative symptoms documented
prior to 1 January 2011 and the risk of hospital
admission during 2011. This year was chosen for
analysis because it maximised the duration of time
over which text would be available for measurement
development, while allowing at least 12 months
follow-up in all instances.
II. Sample B (n=1612): the subset of patients from
sample A who had been discharged from SLaM
inpatient care during 2011. This sample was used
to investigate the relationship between negative
symptoms documented prior to 2011 and the risk
of readmission in the 12 months following
discharge.
III. Sample C (n=1609): the subset of patients from
sample A who received SLaM inpatient care during
2011. This sample was used to investigate the rela-
tionship between negative symptoms documented
prior to 2011 and the length of the ﬁrst hospital
admission during 2011.
Measurement development
Natural language processing (NLP) information extrac-
tion allows structured information to be obtained from
unstructured text records. We used NLP to detect state-
ments in the correspondence ﬁelds of clinical records to
determine references to prespeciﬁed negative symptoms.
Full details of the NLP method are described in a previ-
ous paper.16 In summary, a putative training data set was
selected which contained broad dictionary terms rele-
vant to the negative symptoms of interest (described
below). A detailed review of the training data set was
undertaken by two psychiatrists (RP and RS) to identify
and annotate key phrases within the records that were
either relevant or irrelevant for keywords related to each
symptom. Inter-rater reliability was tested between the
two annotators resulting in percentage agreement of
93.0% (Cohen’s κ 0.85). This training data set was used
to construct an application (CRIS Negative Symptoms
Scale, CRIS-NSS) using a hybrid classiﬁcation model
consisting of a support vector machine (SVM) learning
algorithm21 and rule-based text matching, using the
Generalised Architecture for Text Engineering (GATE)
software package.17 The SVM algorithm was applied
using a ‘bag-of-words’ approach to take into account the
context of negative symptoms within the sentence in
which they were documented, thereby allowing ascer-
tainment of negative symptoms experienced speciﬁcally
by the patient as well as distinguishing between positive
instances and negated instances.16 Once developed,
CRIS-NSS was subsequently used to determine the pres-
ence of negative symptoms within the clinical sample.
The accuracy of CRIS-NSS was evaluated using precision
and recall statistics which were generated through
internal ﬁvefold cross-validation:21 precision, represent-
ing the proportion of text instances identiﬁed by the
tool which were found to be correct in terms of identify-
ing the negative symptom of interest (equivalent to posi-
tive predictive value); and recall, measuring the
proportion of text instances recording a given negative
symptoms which were correctly identiﬁed as such by the
tool (equivalent to sensitivity).
Details of the criteria for ascertaining the negative
symptoms in the CRIS-NSS application are described in
further detail elsewhere;16 brieﬂy, applications were
developed for 10 items: poor motivation, blunted or ﬂat-
tened affect, poor eye contact, emotional withdrawal,
poor rapport, social withdrawal, poverty of speech,
mutism, apathy and concrete thinking. Each of these
symptoms was deﬁned as a binary variable on the basis
of being present at any point in the record within the
deﬁned time period, and a composite scale (range
0–10) was constructed by summing these variables,
followed by Cronbach α score calculation (a measure of
intercorrelation between individual scale items) to esti-
mate its internal consistency. A threshold score of at
least 2 (ie, two or more negative symptoms documented)
was applied a priori to determine the presence or
absence of negative symptoms for analysis as a binary
2 Patel R, et al. BMJ Open 2015;5:e007619. doi:10.1136/bmjopen-2015-007619
Open Access
variable, as well as treating the scale score as an ordinal
variable.
Clinical outcome measures and covariates
The following clinical and demographic variables were
obtained as covariates from the data set: age (on 1
January 2011), gender, marital status, employment
status, and admission and discharge dates for inpatient
care episodes. Using structured data derived from the
Health of the Nation Outcome Scale (HoNOS),22 rou-
tinely completed in SLaM patients, the following sub-
scales (scored 0–4) were used as covariates: activities of
daily living (ADL) impairment, problems with relation-
ships (social impairment), presence of hallucinations or
delusions (a measure of positive symptoms) and depres-
sive symptoms. For all of these HoNOS subscales, binary
variables were deﬁned on the basis of a score of 2 or
more indicating the presence of each construct at levels
judged to be clinically signiﬁcant. In cases with multiple
data points, all covariates were deﬁned as those recorded
closest to 1 January 2011.
Statistical analysis
STATA (V.11) software was used. Estimates of prevalence
of negative symptoms by demographic factors were
obtained as the proportion of patients within each
group with two or more negative symptoms. After
describing the distribution of negative symptoms and
the psychometric properties of the CRIS-NSS, further
analyses were performed to investigate the associations
between the clinical outcomes described above and (1)
the presence of negative symptoms, using binary logistic
regression; and (2) CRIS-NSS scores, using ordinal logis-
tic regression. Reference groups for categorical variables
were generally deﬁned as the most prevalent category,
apart from age group where the youngest group of sufﬁ-
cient size was assigned as the reference. Associations
between negative symptomatology and hospital admis-
sion and readmission were analysed using logistic regres-
sion, while those with length of inpatient stay were
analysed using linear regression—again, estimating asso-
ciations with both the binary and ordinal CRIS-NSS
exposure. For the analyses with hospitalisation outcomes
in/following 2011, CRIS-NSS was generated restricting
information extraction to electronic health records prior
to 2011. Where data were missing on individual covari-
ates (in 2362 participants), this was indicated in the
regression models as a separate category, supplemented
by sensitivity analyses performed on the sample with
complete data on all covariates to check the consistency
of ﬁndings. A further supplementary analysis was per-
formed to test the hypothesis that the association
between negative symptoms and clinical outcomes varies
with age. For this analysis, the previous analyses were
repeated within the subgroups of those aged under the
age of 40 years and those over the age of 40 years and
including an interaction term of age under or over 40
and binary CRIS-NSS exposure. Finally, secondary
analyses were undertaken to investigate and compare
the relationships of individual CRIS-NSS symptoms with
risk of readmission and length of stay using binary logis-
tic and linear regression, respectively.
RESULTS
Performance of CRIS-NSS
Table 1 illustrates results from ﬁvefold cross-validation of
the CRIS-NSS tool. Precision coefﬁcients ranged
between 0.80 and 0.99 and recall between 0.62 and 0.97.
For the composite 10-point scale, the Cronbach α value
was 0.78 indicating a good level of internal consistency.
Prevalence and distribution of negative symptoms
Of the 7678 patients with schizophrenia, 3149 (41.0%)
had at least two negative symptoms documented. Table 1
displays prevalences for each of the symptoms classiﬁed
by the tool. The most frequently recorded symptoms
were poor motivation (30.5%), blunted or ﬂattened
affect (27.4%), poor eye contact (26.0%) and emotional
withdrawal (23.5%). The prevalences by number of symp-
toms were as follows: one symptom 14.6%, two symptoms
12.7%, three symptoms 9.3%, four symptoms 6.4%, ﬁve
symptoms 5.0%, six or more symptoms 7.6%.
Binary logistic regression analyses (table 2) revealed
that patients with two or more negative symptoms were
most likely to be 20–29 years old, male and single. Two
or more negative symptoms were also associated with
ADL impairment, whereas patients who were employed
were less likely to have negative symptoms compared
with those unemployed. Ordinal logistic regression ana-
lysis (etable 1) revealed similar ﬁndings for CRIS-NSS
score as an exposure, and sensitivity analyses limited to
those with full data on all covariates (etable 2) were also
consistent.
Table 1 Performance of Clinical Record Interactive
Search Negative Symptoms Scale (CRIS-NSS) information
extraction applications ascertaining individual symptom
domains
Symptom
Precision/
recall
Prevalence (%)
in patients with
schizophrenia
receiving care
during 2011
(n=7678)
Poor motivation 0.87/0.62 30.5
Blunted or flattened affect 0.93/0.83 27.4
Poor eye contact 0.95/0.79 26.0
Emotional withdrawal 0.85/0.74 23.5
Poor rapport 0.91/0.77 16.3
Social withdrawal 0.94/0.96 12.7
Poverty of speech 0.80/0.73 12.4
Mute 0.99/0.94 8.1
Apathy 0.88/0.97 7.7
Concrete thinking 0.91/0.72 5.7
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Table 2 Binary logistic regression analysis of factors associated with negative symptoms in patients with schizophrenia (n=7678)
Factor Group
Number in
sample
Prevalence of
two or more
negative
symptoms (%)
Association with two or more negative symptoms: OR (95% CI),
p value
Unadjusted Adjusted model (n=7676)*
Age (years) 16–19 203 27.6 0.35 (0.25 to 0.49) <0.001 0.50 (0.35 to 0.71) <0.001
20–29 1337 52.0 Reference Reference
30–39 1775 47.0 0.82 (0.71 to 0.94) 0.006 0.85 (0.73 to 0.99) 0.033
40–49 1983 42.6 0.69 (0.60 to 0.79) <0.001 0.71 (0.61 to 0.82) <0.001
50–59 1137 37.2 0.55 (0.47 to 0.64) <0.001 0.56 (0.47 to 0.67) <0.001
60–69 654 29.1 0.38 (0.31 to 0.46) <0.001 0.39 (0.31 to 0.48) <0.001
70+ 589 18.0 0.20 (0.16 to 0.26) <0.001 0.22 (0.17 to 0.28) <0.001
Gender Male 4592 45.3 Reference Reference
Female 3084 34.7 0.64 (0.59 to 0.71) <0.001 0.77 (0.70 to 0.85) <0.001
Marital status (most recent) Single 5795 44.6 Reference Reference
Married/cohabiting 785 31.6 0.57 (0.49 to 0.67) <0.001 0.76 (0.64 to 0.90) 0.002
Divorced/separated 776 33.4 0.62 (0.53 to 0.73) <0.001 0.85 (0.71 to 1.00) 0.054
Widowed 208 21.2 0.33 (0.24 to 0.47) <0.001 0.77 (0.53 to 1.12) 0.178
Employment (most recent) Unemployed 4956 47.9 Reference Reference
Employed 341 39.6 0.71 (0.57 to 0.89) 0.003 0.68 (0.54 to 0.86) 0.001
In education 311 39.6 0.71 (0.56 to 0.90) 0.004 0.81 (0.63 to 1.03) 0.089
Retired 7 14.3 0.18 (0.02 to 1.51) 0.114 0.40 (0.04 to 3.52) 0.405
ADL impairment Absent 4700 41.9 Reference Reference
Present 2283 46.3 1.20 (1.08 to 1.32) <0.001 1.35 (1.21 to 1.52) <0.001
Social impairment Absent 4432 42.7 Reference Reference
Present 2533 44.4 1.07 (0.97 to 1.18) 0.158 0.94 (0.84 to 1.05) 0.240
Delusions/hallucinations Absent 3904 41.9 Reference Reference
Present 3077 45.0 1.14 (1.03 to 1.25) 0.009 1.19 (1.07 to 1.31) 0.001
Depression Absent 4976 45.2 Reference Reference
Present 2014 38.8 0.77 (0.69 to 0.85) <0.001 0.74 (0.66 to 0.82) <0.001
*Results adjusted for all the factors reported in this table; two cases with no recorded data on gender were dropped.
ADL, activities of daily living.
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Hospital admission, length of stay and readmission
Figure 1 summarises the association of negative symptoms
recorded prior to 2011 with mental health admission
(etable 3) and readmission (etable 4) in 2011. Figure 2
summarises length of hospitalisation for inpatients during
2011 (etable 5). Logistic and linear regression analyses
(table 3) conﬁrmed that negative symptoms were asso-
ciated with a higher likelihood of admission, readmission
and a longer duration of hospitalisation. Speciﬁcally, after
full adjustment (table 3, model 3), patients with two or
more negative symptoms before 2011 had a 24% greater
likelihood of admission during 2011. Moreover, each of
their admissions was, on average, an extra 21 days in
duration, and when they were discharged, they had a 58%
higher risk of readmission within 12 months. All of these
associations remained independent and largely unaltered
following adjustment for intensity of delusions/hallucina-
tions among other covariates. Further analysis (etable 6)
comparing patients aged under and over 40 years showed
that the effects of negative symptoms on inpatient admis-
sion were broadly similar for both groups but with a slight
increase in risk of readmission and reduced duration of
admission in relation to negative symptoms for those
under 40 compared with those over 40. However, the age ×
negative symptoms interaction term remained a non-
signiﬁcant factor (p>0.05) for all models.
Figure 1 Percentage of patients admitted to hospital or readmitted to hospital following discharge in 2011 by number of
negative symptoms.
Figure 2 Median duration of admission among mental health inpatients with schizophrenia in 2011 by number of negative
symptoms (n=1609).
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Finally, logistic and linear regression analyses were per-
formed to examine the relationship between individual
negative symptoms and the frequency and duration of
admission (table 4). Poor eye contact and poor rapport
were associated with increased risk of readmission, while
apathy was associated with increased duration of admis-
sion. Emotional withdrawal and mutism were associated
with both the risk of readmission and the duration of
admission.
DISCUSSION
Using an SVM learning method with an NLP tool, we
were able successfully to extract data on negative symp-
toms from the electronic mental health records of a
large clinical sample of patients with schizophrenia. This
approach did not require any specialised training or
extra clinical assessments, and was able to generate a
scale with robust construct and predictive validity from
data recorded as part of routine clinical care.
The results suggest that negative symptoms are docu-
mented in the electronic health records of a sizeable
proportion of patients with schizophrenia, particularly
in those who are relatively young, male and not in a rela-
tionship, consistent with ﬁndings from studies that
assessed negative symptoms using quite different
methods.23 24 Our ﬁndings were based on the
unprompted documentation of negative symptoms in
the context of routine clinical care by staff who were not
speciﬁcally trained in their assessment. Previous ﬁndings
have usually been based on systematic ratings by a
researcher using a dedicated rating scale. Negative symp-
toms are relatively difﬁcult to detect and assess,1 2 and
may be less frequently documented than positive symp-
toms, such as delusions and hallucinations, because they
are less clinically obvious. In addition, mental health
services in the UK are often orientated towards the man-
agement of acute crises, and hence the treatment of
positive symptoms.25 It is thus possible that the ﬁgures
for the prevalence and the severity of negative symptoms
derived from our approach are lower than would have
been obtained from a trained assessor using a standar-
dised instrument. In addition, our method may be more
likely to identify the types of negative symptoms (eg,
poverty of speech) whose detection does not require
specialised training.
We found that a substantial proportion (41%) of the
sample had at least two negative symptoms. Although we
deﬁned and assessed negative symptoms in different
ways to previous studies, this ﬁgure is comparable to that
described in other samples of patients with schizophre-
nia ( Jager et al4: 44%; Bobes et al23: 58%; Cohen et al24:
40%). Taken together, these ﬁndings suggest that nega-
tive symptoms are a relatively common feature of schizo-
phrenia, rather than being limited to a subgroup of
patients with a chronic, unremitting illness.26
As predicted, we found a clear association between
negative symptoms and poor clinical outcomes, as
indexed by impairments in daily living, increased risk of
admission, increased duration of admission and
increased risk of readmission. Hospital admissions are
the main drivers of cost in the care of patients with
schizophrenia,27 but have traditionally been linked to
the severity of positive psychotic symptoms.28 Our data
indicate that negative symptoms are an equally import-
ant factor, and suggest that a greater emphasis on asses-
sing and treating these features of schizophrenia may
have signiﬁcant health economic beneﬁts. However, as
our ﬁndings are drawn from observational data, it would
be necessary to perform interventional clinical studies to
determine whether an effective treatment for negative
symptoms would lead to better clinical outcomes.
Table 3 Association between number of negative symptoms ascertained prior to 2011 and mental health hospital admission,
readmission and duration of admission in 2011
Inpatient admission
(OR, 95% CI; n=7678)*
Readmission within
12 months of
inpatient admission
(OR, 95% CI; n=1612)*
Duration of inpatient
admission (days;
β-coefficient,
95% CI; n=1609)†
Associations with 2 or more negative symptoms (binary variable)
Unadjusted 1.47 (1.32 to 1.63) 1.73 (1.41 to 2.12) 23.9 (11.2 to 36.7)
1. Age and sex 1.37 (1.23 to 1.53) 1.70 (1.38 to 2.09) 24.1 (11.3 to 36.9)
2. Model 1 plus marital status and employment 1.27 (1.13 to 1.42) 1.58 (1.28 to 1.96) 20.1 (7.1 to 33.1)
3. Model 2 plus delusions/hallucinations, and
depression
1.24 (1.10 to 1.39) 1.58 (1.28 to 1.95) 20.5 (7.6 to 33.5)
Associations with incremental number of negative symptoms (10-point scale ordinal variable)‡
Unadjusted 1.12 (1.09 to 1.15) 1.12 (1.07 to 1.17) 6.5 (3.5 to 9.4)
1. Age and sex 1.09 (1.06 to 1.12) 1.11 (1.06 to 1.16) 6.3 (3.3 to 9.2)
2. Model 1 plus marital status and employment 1.07 (1.04 to 1.10) 1.09 (1.04 to 1.14) 5.4 (2.4 to 8.4)
3. Model 2 plus delusions/hallucinations, and
depression
1.07 (1.04 to 1.10) 1.09 (1.04 to 1.14) 5.6 (2.6 to 8.6)
*Logistic regression.
†Linear regression.
‡ORs and β-coefficients are per one unit increase on the 10-point scale.
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A key strength of our study was the large size of the
patient sample, and that it was representative of the
overall clinical population of people with schizophrenia
in a deﬁned geographic area. Previous studies of negative
symptoms have usually involved smaller patient samples
that were recruited to a research project.4 23 24 Focusing
the information extraction process on text from corres-
pondence maximises the generalisability of our
approach, as letters to primary care physicians (which
accounted for a large portion of the correspondence
text) are unlikely to vary substantially between mental
health services with respect to the language used to
describe the symptoms of interest. In the present study,
we examined the patient’s entire record rather than dis-
crete periods of illness, and it was not possible to delin-
eate the timing or duration of individual negative
symptoms, or whether they were primary (ie, a direct con-
sequence of illness) or secondary (eg, side effects of treat-
ment) as these measures were not routinely documented
in electronic health records. Although we investigated
the association of negative symptoms in clinical docu-
ments prior to 1 January 2011 with outcomes occurring
after 1 January 2011 (to ensure that negative symptoms
were always ascertained prior to outcomes), if negative
symptoms were identiﬁed prior to 1 January 2011, it was
not possible to ascertain when they occurred prior to this
date, or their temporal relationships to subsequent clin-
ical outcomes. The ﬁndings were thus derived from
assessments made over a period that was not standar-
dised, but was generally relatively long. In contrast, most
assessments of negative symptoms in the literature are
derived from a single cross-sectional measurement.29 30
A further limitation of our analysis was the extent to
which individual negative symptoms could be considered
as having equal weight in a composite score. Weighting
the 10 negative symptom applications equally resulted in
a composite score (from 0 to 10) with a reasonable
degree of internal consistency, as demonstrated by a
Cronbach α value of 0.78. However, analysing the associ-
ation of each negative symptom with clinical outcomes
revealed varying degrees of association with poor clinical
outcomes for different negative symptoms. Future
studies are necessary to examine the propensity for dif-
ferent negative symptoms to co-occur in individual
patients and the extent to which different clusters of
symptoms are associated with clinical outcomes, particu-
larly in the light of previous research which suggests that
negative symptoms segregate into two subdomains relat-
ing to amotivation and reduced emotional expression.31
The application of NLP to clinical records is unlikely
to identify negative symptoms as accurately as a direct
assessment using a specialised psychopathological rating
scale. However, automated tools could be used to screen
individuals and identify those with negative symptoms
who would then beneﬁt from comprehensive assessment
using a standardised instrument. In this way, automated
methods could be used to complement standardised
instruments. Automated information extraction tools
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could also be developed to identify other clinical para-
meters from electronic health records in order to
support real-time clinical decision-making. These possi-
bilities could be explored in future research.
In summary, our data suggest that negative symptoms
can be identiﬁed in clinical records using automated
methods, are common in patients with schizophrenia
and are associated with poor clinical outcomes. The
ﬁndings highlight the potential of automated informa-
tion extraction tools in mental health research and clin-
ical practice, and the importance of developing effective
treatments for negative symptoms.
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